For Americans who depend on prescription medication, even a small price increase can strain a household budget. Higher costs can force people to choose between filling a prescription and paying for groceries, utilities or other necessities.
Generic drugs are supposed to provide some relief. They account for most prescriptions filled in the U.S. and generally cost much less than brand-name medications. But lawsuits brought by states allege that some generic drug manufacturers secretly worked together to raise prices rather than competing to lower them.
On October 1, a bipartisan coalition of 48 attorneys general announced a $400 million settlement with Sandoz Inc. and Fougera Pharmaceuticals over allegations involving inflated generic drug prices. Some consumers who bought affected medications may now be entitled to compensation, with a claims deadline of March 8, 2027.
The agreement follows an August announcement that Sandoz had reached an agreement in principle valued at approximately $450 million. That figure included a $400 million payment to participating states, plus approximately $50 million connected to states that had previously settled.
The latest announcement means that consumers who overpaid for generic drugs due to alleged price-fixing are one step closer to getting some of their money back.
Why Did Sandoz Settle the Generic Drug Price-Fixing Lawsuits?
The settlement stems from three lawsuits brought by coalitions of state attorneys general against some of the country's largest generic drug manufacturers.
The states allege companies participated in a broad conspiracy to fix prices, rig bids and divide up the market for more than 100 generic medications rather than compete with each other.
According to the New York Attorney General, pharmaceutical executives allegedly communicated through phone calls, emails and text messages and met at dinners, lunches, cocktail parties and golf outings. The states allege these contacts helped companies coordinate prices, supply and sales.
The drugs involved weren't obscure medications. They included antibiotics, antidepressants, contraceptives and anti-inflammatory medications, as well as drugs used to treat diabetes, cancer, epilepsy, multiple sclerosis, HIV and ADHD. Some alleged coordinated price increases exceeded 1,000%.
Under the settlement, Sandoz will pay approximately $320.6 million plus interest over seven years, bringing the total to $400 million. It must also implement an antitrust compliance program, provide annual training and employ a chief compliance officer.
As is standard with most settlements like this, Sandoz has not admitted wrongdoing.
Who Can Claim Money from Generic Drug Settlements?
The most important question for Americans is whether they may actually get some of the settlement money.
Consumers who bought certain generic prescription drugs between May 1, 2009, and December 31, 2019, may qualify. The participating states have established a settlement website where consumers can search the covered medications and submit a claim.
Consumers can visit AGGenericDrugs.com or call 1-866-290-0182 to check their eligibility. The current deadline for claims for an initial distribution is March 8, 2027.
The compensation process also involves earlier settlements with Glenmark, Lannett, Bausch, Apotex, Heritage and Emcure, which together total approximately $96.5 million.
Consumers do not necessarily need to know which company manufactured every prescription they purchased; the settlement website provides information about the affected drugs and eligibility.
Private Federal Antitrust Settlement with Sun, Taro, and Sandoz
There is also a separate settlement process in the private federal antitrust litigation. Consumers eligible for the Sun/Taro or Sandoz settlement classes must submit claims by November 9, 2026. Both settlements involve drugs purchased between May 1, 2009, and December 31, 2019.
Claim forms and more filing information is available through the official Generic Drugs End Payor Settlement website.
Because the latest settlement with Sandoz is separate of this private antitrust litigation, the two claims processes involve different settlements and deadlines. Consumers who purchased generic drugs during the periods covered should check both rather than assuming one claim covers everything.
Once the deadlines to file a claim pass, consumers will be unable to sue any of the involved companies. State attorneys general are urging people to take part in the settlement.
Why Do Generic Drug Prices Rise?
Generic drugs are cheaper largely because manufacturers are supposed to compete.
FDA research shows that additional generic competition generally drives prices downward. An agency analysis found that with four competitors, generic prices were about 79% lower than the brand-name price before generic competition began. With six or more competitors, prices were more than 95% lower.
That helps explain why alleged drug price-fixing matters.
Having several manufacturers doesn't necessarily produce meaningful competition if companies agree not to aggressively compete against each other. The state lawsuits claim manufacturers instead developed an understanding about pricing and market share, sometimes referring to concepts such as “fair share” and “playing nice in the sandbox.”
Competition can also disappear for legitimate reasons. Manufacturers may leave markets because demand is small, production costs are high or profits become too low. Research has found that markets with fewer manufacturers are particularly vulnerable to higher generic prices.
That means simply seeing several generic versions of a drug at the pharmacy doesn't guarantee the market is functioning competitively.
Will Prescription Drug Settlements Make Medications Cheaper?
Whether the drug price fixing settlements make the cost of prescription drugs cheaper isn’t a guarantee, and they won’t immediately lower prices.
The settlements can return some money to consumers who overpaid. They can also lead to compliance requirements intended to prevent similar conduct. This sends a message to manufacturers that agreements designed to undermine competition can carry substantial financial and operational consequences.
But a settlement does not automatically lower the price of a prescription at the pharmacy tomorrow.
Drug prices are affected by many factors: the number of manufacturers, production costs, shortages, insurance coverage and the complicated system through which drugs reach patients.
The larger significance may be protecting the competition that makes generic drugs affordable in the first place.
According to the FDA, about 90% of U.S. prescriptions are filled with generic drugs. In 2022, the agency’s research found that prices fell about 20% in markets with roughly three generic competitors and as much as 70% to 80% with 10 or more competitors after three years.
For millions of Americans taking medications every day, that competition isn't an abstract antitrust issue. It can determine how much they pay each time they walk up to the pharmacy counter.
